Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma

The purpose of this research study is to see if loncastuximab tesirine has any benefits at dose levels researchers found acceptable in earlier studies in patients with related forms of immune cell cancers. The researchers want to find out the effects (good and bad) that loncastuximab tesirine has on the participant and the participant's condition.

Trial Details

NCT ID

NCT05296070

Phase

PHASE2

Sponsor

University of Miami

Status

RECRUITING

Cancer Type

Non-Hodgkin Lymphoma Lymphoma

Interventions

Loncastuximab tesirine 150 µg/Kg
Loncastuximab tesirine 75µg/Kg

Locations (sample)

Duarte, California, United States|34.13945,-117.97729
Miami, Florida, United States|25.77427,-80.19366
Atlanta, Georgia, United States|33.749,-84.38798
Nashville, Tennessee, United States|36.16589,-86.78444

Key Eligibility Criteria

Men and women, aged 18 years or older.
Histologically confirmed MZL, including extranodal, nodal, and splenic subtypes.
Previously received 1 or more lines of systemic therapy, including at least 1 anti-CD20 antibody (cluster of differentiation antigen 20) (either as…
Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy (defined as the presence of ≥ 1 lesion that measures \> 1.5 cm in the…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Hodgkin Lymphoma Lymphoma Trials on Trialify →